Keystone Financial Group Purchases Shares of 45,400 Caribou Biosciences, Inc. (NASDAQ:CRBU)

Keystone Financial Group acquired a new position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 45,400 shares of the company’s stock, valued at approximately $72,000.

Other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in shares of Caribou Biosciences by 6.5% in the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after purchasing an additional 124,782 shares in the last quarter. US Bancorp DE lifted its stake in Caribou Biosciences by 3,524.2% in the 4th quarter. US Bancorp DE now owns 27,218 shares of the company’s stock valued at $43,000 after acquiring an additional 26,467 shares in the last quarter. Barclays PLC boosted its position in Caribou Biosciences by 122.4% during the 3rd quarter. Barclays PLC now owns 129,839 shares of the company’s stock worth $255,000 after acquiring an additional 71,463 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Caribou Biosciences by 74.4% during the 4th quarter. Thrivent Financial for Lutherans now owns 186,621 shares of the company’s stock worth $297,000 after acquiring an additional 79,636 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of Caribou Biosciences by 9.2% in the fourth quarter. American Century Companies Inc. now owns 159,822 shares of the company’s stock valued at $254,000 after purchasing an additional 13,421 shares during the last quarter. 77.51% of the stock is owned by institutional investors.

Caribou Biosciences Stock Performance

Shares of NASDAQ:CRBU opened at $0.80 on Tuesday. Caribou Biosciences, Inc. has a 52-week low of $0.66 and a 52-week high of $4.39. The company has a market capitalization of $74.42 million, a P/E ratio of -0.48 and a beta of 2.36. The company has a 50-day simple moving average of $1.07 and a 200 day simple moving average of $1.60.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.01. The business had revenue of $2.08 million during the quarter, compared to the consensus estimate of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. As a group, equities analysts forecast that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a research report on Wednesday, March 19th. Bank of America decreased their price objective on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Caribou Biosciences currently has an average rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.